Harvard Bioscience Appoints New CEO, Jeffrey S. Glass
Ticker: HBIO · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, ceo-appointment, board-of-directors
Related Tickers: HBIO
TL;DR
New CEO Jeffrey Glass takes the helm at Harvard Bioscience, replacing interim CEO James Lark.
AI Summary
Harvard Bioscience, Inc. announced on March 21, 2024, the appointment of Jeffrey S. Glass as its new Chief Executive Officer and a member of the Board of Directors, effective immediately. Glass previously served as CEO of Topcon Healthcare and has a background in leading technology companies. The company also announced the departure of its interim CEO, James F. Lark, Jr., who will remain on the Board.
Why It Matters
The appointment of a new CEO often signals a strategic shift or a renewed focus for the company, potentially impacting its future performance and stock value.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty and signal potential strategic shifts, which may carry inherent risks.
Key Players & Entities
- Harvard Bioscience, Inc. (company) — The company filing the report.
- Jeffrey S. Glass (person) — Newly appointed Chief Executive Officer and Board member.
- James F. Lark, Jr. (person) — Departing interim Chief Executive Officer.
- March 21, 2024 (date) — Effective date of the CEO appointment and departure.
FAQ
Who has been appointed as the new CEO of Harvard Bioscience?
Jeffrey S. Glass has been appointed as the new Chief Executive Officer of Harvard Bioscience.
When was the appointment of the new CEO effective?
The appointment of Jeffrey S. Glass as CEO was effective immediately as of March 21, 2024.
Who is the departing interim CEO?
James F. Lark, Jr. is the departing interim CEO.
Will the former interim CEO remain with the company?
Yes, James F. Lark, Jr. will remain on the Board of Directors.
What is Harvard Bioscience's principal executive office address?
Harvard Bioscience's principal executive office is located at 84 October Hill Road, Holliston, MA 01746.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2024-03-26 17:00:49
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The NASDAQ Stock Marke
Filing Documents
- f8k_032624.htm (8-K) — 19KB
- 0001171843-24-001609.txt ( ) — 185KB
- hbio-20240321.xsd (EX-101.SCH) — 3KB
- hbio-20240321_lab.xml (EX-101.LAB) — 33KB
- hbio-20240321_pre.xml (EX-101.PRE) — 22KB
- f8k_032624_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On March 21, 2024, the Compensation Committee of the Board of Directors of Harvard Bioscience, Inc. (the "Company") approved the 2024 annual cash incentive plan (the "Plan"). Pursuant to the Plan, the Company's Chief Executive Officer and Chief Financial Officer have each been assigned a target award amount determined as a percentage of his or her 2024 base salary and will have the opportunity to earn between 0% and 150% of the target award amount based on the achievement of certain pre-defined corporate financial objectives. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD BIOSCIENCE, INC. Date: March 26, 2024 By: /s/ John Fry John Fry Chief Legal Counsel and Secretary